Cue Biopharma Inc
1UC0
Company Profile
Business description
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Contact
40 Guest Street
BostonMA02135
USAT: +1 617 949-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.00 | 14.40 | -0.16% |
| CAC 40 | 8,112.92 | 29.00 | -0.36% |
| DAX 40 | 24,033.15 | 50.38 | -0.21% |
| Dow JONES (US) | 49,149.78 | 18.01 | -0.04% |
| FTSE 100 | 10,310.41 | 10.68 | -0.10% |
| HKSE | 25,679.78 | 245.87 | -0.95% |
| NASDAQ | 24,700.74 | 186.36 | -0.75% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,764.40 | 110.54 | -0.86% |
| S&P 500 | 7,139.99 | 33.92 | -0.47% |
| S&P/ASX 200 | 8,710.70 | 10.50 | -0.12% |
| SSE Composite Index | 4,078.64 | 7.71 | -0.19% |